2022 annual financial data
ImmunityBio 2022 Operating margin
Direct answer
Operating margin was -146,374.17%.
Operating income was -351,298,000 USD and net income was -416,567,000 USD.
Operating cash flow was -337,509,000 USD.
Get free ImmunityBio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 240,000 USD
- Operating income
- -351,298,000 USD
- Net income
- -416,567,000 USD
- Operating cash flow
- -337,509,000 USD